SCHEMBL18613360

SCHEMBL18613360

CC(C)(C)[Si](C)(C)OCc1ccc(OC(=O)CCC(=O)Oc2ccc(CO[Si](C)(C)C(C)(C)C)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ELANE P08246 2/20 0.41
BCL9 O00512 1/20 0.37
CTNNB1 P35222 1/20 0.37
DRD2 P14416 1/20 0.36
NR4A2 P43354 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
BACE1 P56817 1/20 0.35
ESR1 P03372 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18613361 0.94 KMT2A (0.44) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL12909500 0.86 LMNA (0.44) KMT2AALDH1A1LMNAMAPTHSD17B10
SCHEMBL28711315 0.85 ELANE (0.41) KMT2AELANENR4A2RXRARXRB
SCHEMBL26264881 0.85 AR (0.39) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL4590354 0.83 KMT2A (0.44) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL14870985 0.82 ELANE (0.47) ELANEDRD2BACE1
SCHEMBL16610043 0.80 MAPT (0.55) KMT2AALDH1A1MAPTELANEMEN1
SCHEMBL32673207 0.80 BACE1 (0.40) KMT2AALDH1A1LMNAMAPTHTT
SCHEMBL30498581 0.80 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2
SCHEMBL16610054 0.79 SMN1; SMN2 (0.51) KMT2AALDH1A1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118063537-A Prodrugs of directed lymphatics 莫纳什大学 2024-05-24 CN disclosed
CN-108137482-B Prodrugs of directed lymphatics 莫纳什大学 2024-03-15 CN disclosed
US-20240050573-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2024-02-15 US disclosed
US-11738087-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2023-08-29 US disclosed
CN-114031658-A Lymphatic prodrugs 莫纳什大学 2022-02-11 CN disclosed
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2018-08-30 US disclosed
EP-3347340-A1 LYMPH DIRECTING PRODRUGS Monash University (AU) 2018-07-18 EP disclosed
WO-2017041139-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2017-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050573-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN KMT2A 4086/4885ALDH1A1 1056/4885LMNA 3766/4885
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MLNR, ABCB11, MLN KMT2A 3956/4885ALDH1A1 1385/4885LMNA 3302/4885
US-11738087-B2 Lymph directing prodrugs MLNR, ABCB11, MLN KMT2A 3956/4885ALDH1A1 1385/4885LMNA 3302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.